![Foto de MIGUEL](/img/nophoto.png)
MIGUEL
ARRABAL MARTÍN
PROFESOR TITULAR DE UNIVERSIDAD
Argitalpenak (227) MIGUEL ARRABAL MARTÍN argitalpenak
2024
-
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies
OncoImmunology, Vol. 13, Núm. 1
-
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes
Journal of Clinical Oncology, Vol. 42, Núm. 9, pp. 987-993
-
Correlation between breast cancer subtypes determined by immunohistochemistry and n-COUNTER PAM50 assay: a real-world study
Breast Cancer Research and Treatment, Vol. 203, Núm. 1, pp. 163-172
-
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆
Annals of Oncology, Vol. 35, Núm. 2, pp. 159-182
-
Efectividad de la estimulación del nervio tibial posterior en pacientes con vejiga hiperactiva resistentes al tratamiento médico
Enfuro, Núm. 143, pp. 8-12
-
Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer
European Journal of Cancer, Vol. 199
-
Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer
Journal of Clinical Oncology, Vol. 42, Núm. 9, pp. 994-1000
-
Patient-reported outcomes in high-risk HR+ /HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPEB study
European Journal of Cancer, Vol. 196
-
Preliminary results of the external urinary sphincter Uroflex® on the quality of life of patients with male urinary incontinence after prostate surgery: tolerance, severity of incontinence, and quality of life
International Urology and Nephrology
-
Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network—Breast dataset (SCAN-B)
ESMO Open, Vol. 9, Núm. 3
-
Trastuzumab deruxtecan in breast cancer
Critical Reviews in Oncology/Hematology, Vol. 198
2023
-
A randomized, double-blind, placebo-controlled clinical trial of the use of hydroxycitric acid adjuvant to shock wave lithotripsy therapy in patients with calcium stones. Stone fragmentation results
Urolithiasis, Vol. 51, Núm. 1
-
A systematic review of the efficacy of intravesical electromotive drug administration therapy for non-muscle invasive bladder cancer
Urologic Oncology: Seminars and Original Investigations, Vol. 41, Núm. 4, pp. 166-176
-
Adjuvant intravesical treatment in patients with intermediate and high-risk non-muscle-invasive bladder cancer with BCG versus MMC applied with COMBAT or EMDA. Results of a prospective study
Journal of Cancer Research and Clinical Oncology, Vol. 149, Núm. 10, pp. 7453-7459
-
Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer
Annals of Oncology, Vol. 34, Núm. 9, pp. 783-795
-
Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
Clinical Cancer Research, Vol. 29, Núm. 20, pp. 4166-4177
-
Beyond October, Beyond Pink: A Year-Round Revelation for Women’s Breast Health
Journal of Women's Health, Vol. 32, Núm. 11, pp. 1143-1146
-
Complementary and alternative medicine in cancer patients: characteristics of use and interactions with antineoplastic agents
Journal of Cancer Research and Clinical Oncology, Vol. 149, Núm. 7, pp. 2855-2882
-
Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer
Urologic Oncology: Seminars and Original Investigations, Vol. 41, Núm. 2, pp. 109.e1-109.e8
-
Electromotive Drug Administration Chemotherapy with Mitomycin C Versus Bacillus Calmette-Guerin for the Treatment of Non-Muscle Invasive Bladder Cancer
Bladder Cancer, Vol. 9, Núm. 2, pp. 159-166